Evaluates the antitumor efficacy of adenocarcinoma cells (TSA) engineered to release interleukin (IL)-12 in a mouse model system. Comparison of the efficacy of the adenocarcinoma cells with other cytokines; Rejection of the cytokines by most mice; Efficacy of the immune reaction elicited by TSA-IL12 cells in curing mice with TSA tumors.